Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKIPPirr: Prevention of Amivantamab Infusion-Related Reactions
2023-506578-11-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised trial of amivantamab in EGFR-mutated non-small cell lung cancer (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Rate of infusion-related reactions on Cycle 1 Day 1. Started Jan 2024; status: completed.
02
Drugs
amivantamab
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2023-506578-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506578-11-00.